Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Ionis Pharmaceuticals (IONS) and Ono Pharmaceutical announced that the two companies have entered into a license agreement in which Ono obtains ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...

A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care ...

A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess ...